Chemotherapeutic targeting of myeloid-derived suppressor cells

Abstract

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Keywords: :

• cancer
• chemoimmunomodulation
• doxorubicin
• helper T lymphocytes
• myeloid-derived suppressor cells
• ROS

Citation: Alizadeh D, Katsanis E, Larmonier N. Chemotherapeutic targeting of myeloid-derived suppressor cells. OncoImmunology 2013; 2:e27359; 10.4161/onci.27359

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Grant support came from Cancer Biology Training grant T32CA009213, NIH/NCI R01 grant CA104926, and AZ Cancer Center Support Grant CA023074.